Efficacy of GLP 1 Receptor Agonists in Managing Weight Regain Following Roux-en-Y Gastric Bypass: A Therapeutic Avenue to Restore Metabolic Control?
Clicks: 2
ID: 315740
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
0.3
/100
2 views
1 readers
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #129 of 432 articles by views in the british journal of surgery
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 432 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Weight regain after Roux-en-Y gastric bypass (RYGB) can diminish the long-term benefits of bariatric surgery. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) offer a pharmacologic option to counter postoperative weight recurrence. Aims To evaluate the efficacy, tolerability, and impact on quality of life of GLP-1 RAs in patients with weight regain after RYGB. Methods In this retrospective cohort, 70 patients with ≥15% weight regain after RYGB received GLP-1 RA therapy and were followed for 18 months. Primary endpoints were changes in body weight and Body Index Mass (BMI); secondary endpoints included remission of metabolic comorbidities and quality of life assessed by the BAROS score. Results Median total body weight loss (TBWL) reached 12.8% at 18 months. Remission of type 2 diabetes mellitus (T2DM) was observed in 96.6% at 12 months, hypertension remission in 80%, and dyslipidaemia remission in 86%. Quality of life scores improved significantly. Therapy discontinuation occurred in 7.1% of patients. Conclusion GLP-1 RAs appear effective and well tolerated in managing weight regain after RYGB, delivering metabolic improvements and measurable enhancement in quality of life. The durability of these effects beyond treatment requires further investigation.
| Reference Key |
openalex_W7163351747
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | F Da Canal, T Delko, C Di Pietro Martinelli, M Sidler, I Lazaridis, N Potoczna, G Peros, W Gantert |
| Journal | the british journal of surgery |
| Year | 2026 |
| DOI |
10.1093/bjs/znag055.002
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.